Saranas’ transcatheter internal bleeding detector scores FDA de novo clearance

Saranas Early Bird
The device measures changes in electrical resistance across the blood vessel to alert physicians of ruptures or tears during transcatheter procedures. (Saranas)

Saranas has received a de novo clearance from the FDA for its Early Bird system, used to detect internal bleeding in real time during endovascular procedures.

Invented at the Texas Heart Institute, the device includes a sensor-laden vascular access sheath that measures changes in electrical resistance across the blood vessel.

It can alert physicians if the vessel is accidentally torn or injured during transcatheter aortic valve replacements, large-bore hemodynamic support procedures, and other complex interventions where the femoral artery or vein is used.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Peri-procedural bleeding associated with endovascular procedures has a significant impact on patient safety and adds incremental costs to the healthcare system with longer hospital stays and additional interventional treatment,” Saranas’ chief medical officer, Philippe Généreux, M.D., said in a statement.

According to the company, a recent study of over 17,000 large-bore interventions found bleeding complications occurred in about 20% of patients.

RELATED: Saranas raises $2.8M to pilot its internal bleeding detector

The Houston-based Saranas is currently piloting the system in multiple centers to assess its versatility, with a commercial launch planned for select centers of excellence in the U.S., the company said.

“As the first and only device on the market for early bleed detection, we have the potential to significantly reduce bleeding complications and related healthcare costs, while improving clinical outcomes in patients undergoing endovascular procedures,” said Saranas President and CEO Zaffer Syed.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.